Immunogenicity, efficacy and safety of Nuwiq<sup>®</sup> (human‐cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study - Concepedia

Concepedia

Publication | Open Access

Immunogenicity, efficacy and safety of Nuwiq<sup>®</sup> (human‐cl rh<scp>FVIII</scp>) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

DOI Full Paper Access

27

Citations

20

References

2017

Year

Ri Liesner, Marina Abashidze, Olga Aleinikova, Carmen Altisent, Mark Belletrutti, Annie Borel‐Derlon, Manuel Carção, Hérvè Chambost, Anthony K.C. Chan, Leonid Dubey,

Abstract

These interim data show a cumulative incidence of 12.8% for HT inhibitors and convincing efficacy and tolerability in PUPs treated with Nuwiq<sup>®</sup> .

References

	Year	Citations

Page 1